Formulation and characterization of floating matrix tablets for an antihypertensive drug: Valsartan
Himmat Singh Chawra, YS Tanwar and SK Singh
Valsartan is an angiotensin receptor blocker (ARB) drug that may be used to treat a variety of cardiac conditions, including hypertension, diabetic nephropathy and heart failure. The aim of the present study was to develop floating matrix tablets of Valsartan. The floating matrix tablets of Valsartan were prepared based on hydrophilic matrix and low density copolymer that retains the dosage form in the stomach. The prepared tablets were evaluated for various pre-compression & post-compression parameters, in vitro drug release and in vivo X-ray imaging in rabbits. All tablets showed excellent swelling and floating capabilities, short floating lag times and maintained controlled release for more than 17 h. The release of Valsartan from optimized formulation F13 was found to be non-Fickian type. Gastric X-ray imaging of formulation F13 (Containing drug, Chitosan, Carbopol-940, Poly (Styrene Divinyl Benzene), Lactose, Magnesium Stearate and Talc) showed that the floating matrix tablet was continuously floating in the stomach region of the rabbit; hence, it could prolong the gastric retention time to more than 12 h. These results indicated that developed matrix tablets of Valsartan could be successfully used for floating drug delivery system.
How to cite this article:
Himmat Singh Chawra, YS Tanwar, SK Singh. Formulation and characterization of floating matrix tablets for an antihypertensive drug: Valsartan. Pharma Innovation 2018;7(9):09-16.